(NASDAQ: THTX) Theratechnologies's forecast annual revenue growth rate of 16.05% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Theratechnologies's revenue in 2025 is $62,004,195.On average, 1 Wall Street analysts forecast THTX's revenue for 2025 to be $3,857,723,594, with the lowest THTX revenue forecast at $3,857,723,594, and the highest THTX revenue forecast at $3,857,723,594. On average, 1 Wall Street analysts forecast THTX's revenue for 2026 to be $4,308,327,780, with the lowest THTX revenue forecast at $4,308,327,780, and the highest THTX revenue forecast at $4,308,327,780.
In 2027, THTX is forecast to generate $4,395,689,816 in revenue, with the lowest revenue forecast at $4,395,689,816 and the highest revenue forecast at $4,395,689,816.